{"entity":{"id":"nct01064466","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","aka":[],"tldr":"A phase 2/3 trial of Etoposide in small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, active and no longer recruiting.","summary":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT01064466 by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, with 600 participants enrolled, started 2025-07-16 and due to reach its primary completion in 2026-11-18. Interventions recorded: ETOPOSIDE - Usual and ETOPOSIDE - Study.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01064466","url":"https://clinicaltrials.gov/study/NCT01064466"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["etoposide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT01064466","phase":"2/3","setting":"Explore the Relationship Between Single Nucleotide Polymorphisms and Etoposide Response and Toxicity in Patients With Small Cell Lung Cancer.","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair","enrolled":600,"outcomes":[]},"route":"/trials/nct01064466/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}]}}